OTCMKTS:ONPH Oncology Pharma (ONPH) Stock Price, News & Analysis → AI finds its first serious application (From Wall Street Star) (Ad) Free ONPH Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1,286 shsAverage Volume7,759 shsMarket Capitalization$4,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Oncology Pharma alerts: Email Address Ad Prosper Trading AcademyThese AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy About Oncology Pharma Stock (OTCMKTS:ONPH)Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California.Read More Ad Prosper Trading AcademyThese AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy ONPH Stock News HeadlinesApril 23, 2024 | bizjournals.comPeninsula biopharma wins 1st FDA approval for drug targeting type of brain cancer in kidsApril 17, 2024 | markets.businessinsider.comNika Pharmaceuticals, Inc. (NKPH) Purchased the Technologies for Three Drugs in Tablet Form and One Dietary SupplementApril 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 12, 2024 | bloomberg.comNuclear Medicine Is Big Pharma’s New Target in Cancer RaceApril 10, 2024 | businesswire.comOnchilles Pharma Presents at AACR 2024 New Preclinical Data for N17350 and N17465 Demonstrating the Potential for Potent and Tumor-Selective TreatmentApril 9, 2024 | msn.comBoehringer Ingelheim Upbeat On China, Forms Cancer Drug PartnershipApril 4, 2024 | msn.comKintara and TuHURA enter merger deal to advance oncology pipelineApril 4, 2024 | msn.comCancer biotech firm Alterome Therapeutics raises $132 mln in Goldman Sachs-led roundApril 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 4, 2024 | msn.comA new hope in immunotherapy against cancerMarch 26, 2024 | msn.comRegeneron's blood cancer therapy faces setback as FDA raises trial concernsMarch 25, 2024 | msn.comUS FDA declines to approve Regeneron's blood cancer therapyMarch 21, 2024 | bizjournals.comClinical trial results show new Penn technology could be the key to fighting brain cancerMarch 12, 2024 | msn.comAbilityPharma receives funds to advance pancreatic cancer trialMarch 4, 2024 | msn.comIovance stock rises after FDA lifts clinical hold on lung cancer trialFebruary 27, 2024 | benzinga.comOncology Pharma Stock (OTC:ONPH) Dividends: History, Yield and DatesFebruary 27, 2024 | benzinga.comOncology Pharma Stock (OTC:ONPH), Analyst Ratings, Price Targets, PredictionsFebruary 20, 2024 | msn.comThe doctor behind the next big thing in cancer treatmentFebruary 20, 2024 | msn.comThe woman behind the next big thing in cancer treatmentFebruary 19, 2024 | msn.comPositive signs for new cancer treatment after trial on Oxford patientsFebruary 17, 2024 | msn.comUPDATE 3-US FDA grants accelerated approval for Iovance's skin cancer cell therapyFebruary 16, 2024 | reuters.comUS FDA grants accelerated approval for Iovance's skin cancer cell therapyFebruary 15, 2024 | msn.comCancer breakthrough as doctors celebrate new ‘wonder drug’February 15, 2024 | msn.comOno and Numab to develop antibody for cancer treatmentFebruary 9, 2024 | msn.comBoehringer and CBmed partner to develop cancer therapiesFebruary 4, 2024 | tmcnet.comAccord Healthcare partners with ITN Business for World Cancer Day to explore how innovative approaches are helping shape the future of cancer careFebruary 2, 2024 | msn.comNeoPhore adds $12.2m in Series B extension for immuno-oncology pipelineSee More Headlines Receive ONPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncology Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Prepackaged software Sub-IndustryN/A Current SymbolOTCMKTS:ONPH CUSIPN/A CIKN/A Webwww.oncology-pharma.com Phone(415) 869-1038Fax858-385-8997Employees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares38,660,000Free Float31,704,000Market Cap$4,000.00 OptionableNot Optionable Beta-0.91 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Chuck WagnerPresident, Treasurer & ChairmanMr. George MalesekInterim Chief Executive OfficerMr. Dimitri Theofilopolous Esq.Legal CounselKey CompetitorsUPDOTCMKTS:UPDCBohai Pharmaceuticals GroupOTCMKTS:BOPHImageWorksOTCMKTS:IWKSMedifocusOTCMKTS:MDFZFViatar CTC SolutionsOTCMKTS:VRTTView All Competitors ONPH Stock Analysis - Frequently Asked Questions How do I buy shares of Oncology Pharma? Shares of ONPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ONPH) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncology Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
